Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors.

Neumiller, Joshua J; Lienhard, Fredrick J; Alicic, Radica Z; Tuttle, Katherine R.

Afiliação

Neumiller JJ; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Lienhard FJ; Providence Medical Research Center, Providence Health and Services, Spokane, WA, USA.
Alicic RZ; College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA.
Tuttle KR; Providence Medical Research Center, Providence Health and Services, Spokane, WA, USA.

touchREV Endocrinol ; 18(2): 106-115, 2022 Nov.

Article em En | MEDLINE | ID: mdl-36694888

Palavras-chave

Atherosclerotic cardiovascular disease; cardiovascular outcome trials; diabetic kidney disease; heart failure; sodium glucose cotransporter-2 inhibitors; type 2 diabetes

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article